Is It Bad to Take Omeprazole Long Term?

Long-term omeprazole use carries real but generally modest risks, and for many people with a genuine medical need, the benefits outweigh those risks. The concerns are not hypothetical: years of daily use have been linked to nutrient deficiencies, a higher chance of certain infections, and possible effects on kidney function and bone strength. But the size of these risks is often smaller than headlines suggest, and large studies looking at overall mortality have found that long-term users, when analyzed carefully, do not appear to die at higher rates than nonusers. The important question is not whether omeprazole is “bad” in the abstract but whether you still need it, and whether anyone has reassessed that in a while.

How Omeprazole Suppresses Acid

Omeprazole belongs to a class of drugs called proton pump inhibitors. It works by blocking the enzyme responsible for the final step of acid production in the stomach’s acid-secreting cells. This is a powerful mechanism: daily doses in the standard range shut down roughly 80 to 100 percent of stimulated acid output within a few hours, and even 24 hours after a dose, acid secretion remains suppressed by about half or more.¹ Because it blocks acid regardless of what triggered the secretion, omeprazole is more effective than older acid-reducing drugs that only work on one trigger pathway.² That potency is exactly why it works so well for conditions like severe reflux, Barrett’s esophagus, and ulcer prevention. It is also why the consequences of years-long acid suppression deserve attention.

Magnesium and Vitamin B12 Deficiencies

Your stomach acid does more than digest food. It helps your body absorb certain nutrients, and suppressing it for months or years can quietly create deficiencies. The two best-documented are magnesium and vitamin B12.

Low magnesium from omeprazole use has been recognized as a genuine side effect. The drug appears to interfere with how the intestines absorb magnesium, likely by changing the pH environment that magnesium transport channels need to work properly.³ Most people on omeprazole never notice a problem, but in rare cases the drop in magnesium can be severe enough to cause dangerous heart rhythm disturbances.⁴ The FDA has issued warnings about this. Low sodium and low calcium have also been reported.⁵

Vitamin B12 is another concern. Your stomach needs acid to separate B12 from the proteins it is bound to in food. With that acid suppressed, less B12 gets freed up for absorption. One study of long-term PPI users found B12 deficiency in about 29 percent of patients, a rate higher than standard blood tests alone would catch.⁶ Research has also confirmed that omeprazole measurably reduces B12 absorption at both standard and higher doses.⁷ B12 deficiency can cause fatigue, nerve problems, and cognitive symptoms, so if you have been on omeprazole for more than a year, it is worth asking your doctor about periodic blood work.

Bone Fracture Risk

The link between long-term omeprazole use and bone fractures has generated a lot of worry, and the FDA added a fracture warning to PPI labels back in 2010. Pooled analyses of observational studies do suggest that long-term or high-dose PPI use is associated with a modestly higher risk of fractures, particularly hip fractures.⁸ Animal and human data have also shown decreases in bone mineral density with prolonged use.⁹

However, the picture gets murkier when researchers account for all the other things that affect fracture risk. One large study of elderly patients found that after adjusting for age, sex, and known fracture risk factors, chronic omeprazole use was no longer an independent predictor of fractures. In fact, among the oldest patients (85 and older), omeprazole users actually had a lower fracture rate.¹⁰ This does not mean the concern is baseless, but it suggests that the people who end up on long-term PPIs tend to have other health issues that also raise fracture risk, and separating the drug’s effect from those background risks is difficult. If you have osteoporosis or other risk factors for fractures, it is a conversation worth having with your doctor.

Kidney Concerns

Kidney risk is one of the more serious concerns in the long-term omeprazole discussion. PPIs are now recognized as a common cause of a type of kidney inflammation called acute interstitial nephritis. This reaction is tricky because it often develops slowly, without the classic allergic signs you might expect from a drug reaction, and can go undetected for months.¹¹ Population-level data from the FDA’s adverse event database have detected strong signals linking PPIs to both acute kidney injury and chronic kidney disease, with the chronic kidney disease signal being the stronger of the two.¹²

One observational study found that omeprazole users with existing kidney disease were much more likely to see their kidney function decline further compared to nonusers.¹³ That study had a small sample size and a very high hazard ratio that likely reflects its specific patient population rather than the risk for everyone, but the direction of the finding is consistent with larger analyses. Among all the potential harms of long-term omeprazole, kidney effects are arguably the ones with the most consistent signal across different study designs. If you are a long-term user, periodic checks of kidney function are reasonable.

Infections and Gut Changes

Stomach acid serves as a barrier against swallowed bacteria and other pathogens. When that barrier is lowered for months or years, certain infections become more likely. Two have received the most attention: Clostridioides difficile (C. diff) infection and pneumonia.

C. diff is a bacterium that causes severe diarrhea and can be life-threatening, especially in hospitalized or elderly patients. Research suggests PPIs raise C. diff risk primarily by changing the pH of the gut rather than through any direct effect of the drug on gut bacteria.¹⁴ A case-control study found that hospitalized patients on omeprazole were about twice as likely to develop C. diff compared to controls.¹⁵ A dose-response meta-analysis found that the per-dose risk increase was not statistically strong, but each additional day of PPI therapy was associated with a small, cumulative uptick in C. diff risk.¹⁶

Pneumonia risk also appears elevated, though the mechanism is different: with less stomach acid to kill bacteria, more oral and stomach bacteria survive to be aspirated into the lungs. A large self-controlled case series found that PPI use was associated with a roughly 73 percent higher rate of pneumonia.¹⁷ A population-based case-control study estimated that about 4 percent of community-acquired pneumonia cases in its population could be attributed to PPI use.¹⁸ In older adults specifically, the risk remained elevated even in the second year of treatment.¹⁹

Beyond specific infections, omeprazole shifts the overall composition of your gut microbiome. Studies have found that PPI users carry significantly more oral bacteria in their stool, including species that are normally kept out of the lower gut.²⁰ Even short courses of omeprazole change stool culture results within days, with higher doses reducing microbial diversity more.²¹ A seven-day course was enough to increase certain Streptococcus and Veillonella species, though those shifts partially reverted after stopping.²² The long-term health significance of these microbiome shifts is still being worked out, but they may partly explain the increased infection susceptibility.

The Dementia Question

For a while, alarming headlines claimed PPIs might cause dementia. Early observational studies did find a statistical association, and researchers proposed plausible mechanisms involving amyloid-beta metabolism in the brain.²³ But better-designed studies have not borne this out. A prospective cohort study using cognitive testing found that PPI use was not associated with incident dementia or measurable cognitive decline over time.²⁴ Another large study of elderly patients actually found that chronic omeprazole use was associated with a lower risk of dementia and cognitive decline, with a roughly 23 percent reduction after adjusting for multiple factors.²⁵ The current weight of evidence is reassuring: if PPIs affect dementia risk at all, the effect is likely very small and may not exist in the direction people feared.

Gastric Cancer and Hypergastrinemia

When you suppress stomach acid for a long time, your body responds by pumping out more of the hormone gastrin, which normally stimulates acid production. Chronically elevated gastrin levels can cause overgrowth of certain hormone-producing cells in the stomach lining, which has raised theoretical concerns about stomach cancer.²⁶ In practice, gastric tumors that develop in long-term PPI users are rarely reported, and those that have been identified tend to behave in a slow, non-aggressive manner that distinguishes them from the more dangerous sporadic tumors that arise independently of PPI use.²⁷ The concern is real enough to mention and for researchers to keep watching, but the actual risk to an individual long-term user appears very low.

Cardiovascular Risk and Drug Interactions

Observational data have linked PPI use to modestly higher rates of heart attacks and strokes. One large study found that current PPI users had about a 13 percent higher rate of ischemic stroke and a 31 percent higher rate of heart attack compared to nonusers, with higher doses carrying greater risk.²⁸ How much of this is caused by the drug itself versus the health profile of the people who end up on PPIs remains debated. PPI users tend to be older and sicker than nonusers, making it hard to isolate the drug’s contribution.

One cardiovascular concern, however, is well-established: omeprazole specifically interferes with the blood thinner clopidogrel. Clopidogrel is a prodrug, meaning the body has to convert it into its active form using an enzyme called CYP2C19. Omeprazole competes for that same enzyme, reducing clopidogrel’s ability to prevent blood clots.²⁹ A clinical crossover trial found that when patients started omeprazole, the proportion who were effectively “nonresponders” to clopidogrel jumped from about 26 percent to 45 percent. In contrast, pantoprazole, a different PPI, did not cause the same problem.³⁰ A nationwide cohort study confirmed that patients on both clopidogrel and omeprazole had a significantly higher risk of ischemic stroke compared to those on clopidogrel alone.³¹ If you take clopidogrel, this is one of the most important things to know about omeprazole. Your doctor can switch you to a PPI that does not share this interaction, or consider an alternative acid-suppressing strategy altogether.

What the Overall Mortality Data Actually Show

Given all these individual risks, you might expect long-term omeprazole users to have clearly higher death rates. The reality is more nuanced. A large study that tracked PPI users over time found that when you account for something called protopathic bias (the tendency for sick people to start PPIs shortly before they are diagnosed with something serious, making the drug look like the cause), the apparent mortality risk largely disappears. With this correction, long-term PPI users actually had about a 10 percent lower mortality rate than nonusers.³²

A separate large prospective study found a similar pattern: initial associations between PPI use and higher death rates were largely weakened or disappeared once the researchers applied lag times and compared PPIs to other acid-reducing drugs rather than to no treatment at all. The authors concluded that their results did not support a real connection between PPI use and increased mortality from major causes.³³ This does not erase the specific risks discussed above, but it does suggest that the net effect of appropriate long-term PPI use is not the catastrophe some coverage implies.

Rebound Acid and How to Stop

One of the most frustrating aspects of long-term omeprazole use is how hard it can be to stop. After weeks or months of acid suppression, your stomach compensates by increasing its capacity to produce acid. When you abruptly stop the drug, acid production can temporarily surge above the level it was at before you started, a phenomenon called rebound acid hypersecretion. This can cause heartburn and reflux symptoms that feel even worse than what sent you to the drug in the first place, convincing many people they still “need” it.³⁴ Studies have shown that rebound can occur in people without Helicobacter pylori infection after as little as eight weeks of PPI use.³⁵

The key takeaway is that feeling worse when you stop does not necessarily mean you need the drug. Tapering appears to work better than quitting cold turkey. A systematic review found that across multiple studies, between 14 and 64 percent of patients successfully discontinued their PPI without worsening symptoms, and gradual tapering was more effective than abrupt cessation.³⁶ A common approach is to step down to a lower dose, then switch to on-demand use where you only take a PPI when symptoms flare.³⁷ One prospective study found that about 80 percent of patients could step down from twice-daily to once-daily dosing without their reflux symptoms returning over six months, though patients who had been on PPIs the longest had a harder time stepping down.³⁸

Alternatives When You Need Less Acid Suppression

Not everyone on a long-term PPI truly needs one. For milder symptoms, or once an ulcer has healed and you just need maintenance protection, histamine-2 receptor antagonists (H2 blockers like famotidine) are a less potent option that carry fewer of the long-term concerns. The trade-off is real, though: in head-to-head comparisons among people taking daily aspirin (who need stomach protection), the famotidine group had significantly more gastrointestinal symptoms and a higher rate of recurrent ulcers than the omeprazole group.³⁹ A randomized trial confirmed that omeprazole was the stronger protector against stomach damage in high-risk aspirin users.⁴⁰ So H2 blockers are not an equal swap for everyone, but they can be a reasonable step-down for people whose condition does not require the full force of a PPI.

A newer class of acid-suppressing drugs called potassium-competitive acid blockers (vonoprazan is the best-known) has been introduced in some countries. A meta-analysis comparing vonoprazan to PPIs for reflux disease found similar effectiveness and similar rates of side effects.⁴¹ Whether vonoprazan offers a better long-term safety profile than omeprazole is not yet clear, since it has not been in widespread use long enough for the kind of decade-long outcome data that PPIs now have.

PPIs in Children

Omeprazole and other PPIs are sometimes prescribed to infants and children with severe reflux, and the safety picture in younger patients deserves its own mention. A systematic review covering over 760,000 pediatric cases found that side effects were reported in about 7 percent of the total, with secondary infections being the most common category, followed by gastrointestinal complaints like diarrhea and vomiting. The review also noted associations with bone fractures, psychiatric effects, and asthma in children, though these were uncommon.⁴² Pediatric use is especially worth scrutinizing because reflux in infants often resolves on its own, meaning many young children may be on PPIs longer than they need to be. The same principles apply for children as for adults: periodic reassessment of whether the drug is still necessary, and awareness that stopping may require a gradual approach to avoid rebound symptoms.